AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16776928 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 217
Study 16776928 — intervention group
Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 217
Study 12631045 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitored desflurane anesthesia
Number of subjects: 160
Study 12631045 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitored propofol anesthesia
Number of subjects: 160
Study 12631045 — intervention group
Group type: COMPARATOR
Intervention: Non-monitored desflurane anesthesia
Number of subjects: 160
Study 12631045 — intervention group
Group type: COMPARATOR
Intervention: Non-monitored propofol anesthesia
Number of subjects: 160
Study 10856535 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 35
Study 10856535 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 35
Study 10856535 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 120 mg/day
Number of subjects: 35
Study 10856535 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg/day
Number of subjects: 35
Study 9021345 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 120 mg/day
Number of subjects: 20
Study 9021345 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 240 mg/day
Number of subjects: 20
Study 9021345 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 480 mg/day
Number of subjects: 20
Study 9021345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U40 Velasulin (15 IU)
Number of subjects: 18
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U100 Velasulin (15 IU)
Number of subjects: 18
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U40 Insulatard (20 IU)
Number of subjects: 18
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U100 Insulatard (20 IU)
Number of subjects: 18
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U40 Mixtard (20 IU)
Number of subjects: 18
Study 1392436 — intervention group
Group type: EXPERIMENTAL
Intervention: U100 Mixtard (20 IU)
Number of subjects: 18
Study 3882735 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg/day)
Number of subjects: 0
Study 3882735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28891027 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate monohydrate 3 mg/kg twice a day orally for 10 days along with standard antibiotics
Number of subjects: 18
Study 28891027 — intervention group
Group type: COMPARATOR
Intervention: No zinc (antibiotic treatment only)
Number of subjects: 18
Study 28891027 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 18
Study 27855872 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (clinic events, community events, and radio messaging) for 6 months
Number of subjects: 306
Study 27855872 — intervention group
Group type: COMPARATOR
Intervention: Standard care control for 6 months
Number of subjects: 306
Study 27855872 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (with coverage greater than 35%)
Number of subjects: 306
Study 24095088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultations in primary care clinics
Number of subjects: 82
Study 22094451 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ablation system (EAS)
Number of subjects: 51
Study 20798191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen with SPF 60 applied twice a day for 28 days
Number of subjects: 110
Study 20798191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18687989 — intervention group
Group type: EXPERIMENTAL
Intervention: NdFeB magnet device
Number of subjects: 45
Study 18687989 — intervention group
Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 45
Study 18687989 — intervention group
Group type: COMPARATOR
Intervention: Transfer tray
Number of subjects: 45
Study 16983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) 30 ml once a day for 10 days
Number of subjects: 48
Study 16983914 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy plus NPPV (Control)
Number of subjects: 48
Study 16983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 48
Study 12906185 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated spiral CT using MSCT scanners
Number of subjects: 0
Study 12906185 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery motion measurement
Number of subjects: 0
Study 12452216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/kg (Group I)
Number of subjects: 60
Study 12452216 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg (Group II)
Number of subjects: 60
Study 12452216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 microg/kg administered prior to skin incision, median sternotomy, CPB, and after coming off CPB
Number of subjects: 60
Study 12452216 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 mg/kg administered at the same time periods as sufentanil
Number of subjects: 60
Study 12452216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil group
Number of subjects: 60
Study 12452216 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl group
Number of subjects: 60
Study 12452216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil and Fentanyl
Number of subjects: 60
Study 12452216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 60
Study 12452216 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 10626336 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis 7.5 mg
Number of subjects: 630
Study 10626336 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis 15 mg
Number of subjects: 630
Study 10626336 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis (dose increased from 7.5 mg to 15 mg in poor responders)
Number of subjects: 630
Study 7732154 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (together condition)
Number of subjects: 26
Study 7732154 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (together condition) in high stress
Number of subjects: 26
Study 7732154 — intervention group
Group type: COMPARATOR
Intervention: Social support (alone condition)
Number of subjects: 26
Study 7732154 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress condition
Number of subjects: 26
Study 7732154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress condition
Number of subjects: 26
Study 1981434 — intervention group
Group type: EXPERIMENTAL
Intervention: Active grenz ray therapy (4 Gy, 10 kV, applied 6 times at 1-week intervals)
Number of subjects: 15
Study 1981434 — intervention group
Group type: COMPARATOR
Intervention: Stimulated therapy (control)
Number of subjects: 15
Study 6757467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guerin (BCG) immunotherapy
Number of subjects: 66
Study 6757467 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 30723114 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome-derived tiled peptide arrays
Number of subjects: 172
Study 30723114 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry analysis
Number of subjects: 172
Study 30723114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiled peptide arrays
Number of subjects: 172
Study 27766712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate in GIC
Number of subjects: 60
Study 27766712 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% aqueous miswak in GIC
Number of subjects: 60
Study 27766712 — intervention group
Group type: COMPARATOR
Intervention: Deionized water in GIC (control)
Number of subjects: 60
Study 25338776 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine or venlafaxine (antidepressants)
Number of subjects: 149
Study 24518937 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 2 hours before surgery and 12.5 mg of heavy bupivacaine 0.5% intrathecally
Number of subjects: 78
Study 24518937 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg plus 12.5 mg of heavy bupivacaine 0.5%
Number of subjects: 78
Study 22028408 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-h fast
Number of subjects: 8
Study 22028408 — intervention group
Group type: COMPARATOR
Intervention: 10-h overnight fast
Number of subjects: 8
Study 19717886 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D image-based planning
Number of subjects: 6
Study 19717886 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DCT image-based planning
Number of subjects: 6
Study 19717886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking regimen
Number of subjects: 6
Study 19717886 — intervention group
Group type: COMPARATOR
Intervention: Static conventional and gated radiotherapy
Number of subjects: 6
Study 17519078 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Alutard SQ (ASQ)
Number of subjects: 0
Study 15132762 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 19
Study 15132762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12166543 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SS)
Number of subjects: 224
Study 12166543 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OC)
Number of subjects: 224
Study 12166543 — intervention group
Group type: COMPARATOR
Intervention: Pitressin plus Nitroglycerine (PN)
Number of subjects: 224
Study 9734620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion)
Number of subjects: 167
Study 8208176 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice obstetric clinics (n = 18)
Number of subjects: 42
Study 8208176 — intervention group
Group type: COMPARATOR
Intervention: Hospital obstetric clinics (n = 24)
Number of subjects: 42
Study 2722269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home staff training in care for the dying
Number of subjects: 306
Study 2722269 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 306
Study 4920799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Number of subjects: 0
Study 4920799 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavine
Number of subjects: 0
Study 4920799 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31994278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical compound containing Ilex paraguariensis, White Mulberry and Chromium Picolinate (500 mg), taken once a day for 3 months.
Number of subjects: 0
Study 31994278 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken once a day for 3 months.
Number of subjects: 0
Study 29063490 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory training
Number of subjects: 45
Study 29063490 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 45
Study 29063490 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 27911621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming for Health intervention group (exergaming and classroom curriculum)
Number of subjects: 80
Study 27911621 — intervention group
Group type: COMPARATOR
Intervention: Control group (classroom curriculum alone)
Number of subjects: 80
Study 27911621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming for Health intervention group
Number of subjects: 80
Study 27911621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 24393610 — intervention group
Group type: EXPERIMENTAL
Intervention: EMMS supplementation and schooling ≥6 years
Number of subjects: 3625
Study 24393610 — intervention group
Group type: EXPERIMENTAL
Intervention: EMMS supplementation and schooling <6 years
Number of subjects: 3625
Study 24393610 — intervention group
Group type: COMPARATOR
Intervention: Standard program and schooling ≥6 years
Number of subjects: 3625
Study 22980375 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic measures
Number of subjects: 15
Study 19933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN; 0.6 mg/h) for 2 hours on 1 day only
Number of subjects: 24
Study 19933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN for 2 hours/day for 7 days
Number of subjects: 24
Study 19933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with transdermal GTN for 7 days
Number of subjects: 24
Study 19933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of vitamin C after continuous GTN therapy
Number of subjects: 24
Study 19933412 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 24
Study 19791552 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypass grafting supplemented by gene stimulators of angiogenesis (gene constructions with the genes of vascular endothelial growth factor, and angiogenin)
Number of subjects: 38
Study 19791552 — intervention group
Group type: COMPARATOR
Intervention: Reconstructive vascular operation alone
Number of subjects: 38
Study 15939567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 193
Study 15939567 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control condition
Number of subjects: 193
Study 14636809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways intervention
Number of subjects: 470
Study 12903463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gossypol (15 mg/d for 12 weeks, then 10 mg/d for 32 weeks)
Number of subjects: 23
Study 12903463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 9333168 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (2 mL of 720 ELISA units/mL) given to HIV-infected men either 1 or 6 months apart; HIV-uninfected men received vaccine at study entry and at 6 months.
Number of subjects: 134
Study 8448264 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 41
Study 8448264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels
Number of subjects: 41
Study 8448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin response
Number of subjects: 41
Study 8448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood tryptophan levels
Number of subjects: 41
Study 8448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan/LNAA ratio
Number of subjects: 41
Study 3096634 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel and Ethinyl Estradiol as an oral tablet
Number of subjects: 24
Study 3096634 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel and Ethinyl Estradiol as a solution
Number of subjects: 24
Study 3407613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsically labeled beef (100 g)
Number of subjects: 12
Study 3407613 — intervention group
Group type: COMPARATOR
Intervention: Extrinsically labeled beef (100 g)
Number of subjects: 12
Study 30777447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 30777447 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 0
Study 28526377 — intervention group
Group type: EXPERIMENTAL
Intervention: OJ group (500 mL/d of 100% orange juice)
Number of subjects: 78
Study 28526377 — intervention group
Group type: COMPARATOR
Intervention: Control group (RCD without OJ)
Number of subjects: 78
Study 26194655 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week brisk walking program (Experimental Group)
Number of subjects: 86
Study 26194655 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 86
Study 24334780 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with an additional escalating reinforcement scheme (n = 72)
Number of subjects: 136
Study 24334780 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 64)
Number of subjects: 136
Study 21546203 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (socio-cognitive intervention with pedometer)
Number of subjects: 65
Study 21546203 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 65
Study 21546203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 19182698 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day of MF101
Number of subjects: 217
Study 19182698 — intervention group
Group type: COMPARATOR
Intervention: 5 g/day of MF101
Number of subjects: 217
Study 16813739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management of diabetes
Number of subjects: 0
Study 16813739 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study 16813739 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 0
Study 16813739 — intervention group
Group type: COMPARATOR
Intervention: Contemporary coronary revascularization (angioplasty)
Number of subjects: 0
Study 12453926 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 1.5 mg kg(‐1)
Number of subjects: 96
Study 12453926 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.15 mg kg(‐1)
Number of subjects: 96
Study 10892897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerazette (75 microg desogestrel)
Number of subjects: 24
Study 10892897 — intervention group
Group type: EXPERIMENTAL
Intervention: Liseta (150 microg desogestrel and 1.5 mg 17beta‐estradiol)
Number of subjects: 24
Study 10892897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of 150 microg etonogestrel
Number of subjects: 24
Study 10892897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerazette (multiple dosing, 1 tablet once daily for 7 days)
Number of subjects: 24
Study 10892897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerazette (single-dose treatments)
Number of subjects: 24
Study 7734230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rearthroplasty group
Number of subjects: 12
Study 7734230 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-reoperated patients)
Number of subjects: 12
Study 1828158 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 0
Study 1828158 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 7269326 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements analysis
Number of subjects: 0
Study 30648358 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761® (Ginkgo biloba extract)
Number of subjects: 0
Study 28768538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 0
Study 28768538 — intervention group
Group type: COMPARATOR
Intervention: Anterior neurectomy
Number of subjects: 0
Study 26003313 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit Finding Scale (BFS-C) at T1
Number of subjects: 658
Study 26003313 — intervention group
Group type: EXPERIMENTAL
Intervention: Worldview, family relationship, social relationship, and acceptance at T1
Number of subjects: 658
Study 26003313 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal growth, worldview, family relationship, and acceptance at T1
Number of subjects: 658
Study 23394825 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) intervention
Number of subjects: 22
Study 23394825 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating (HE) education control group
Number of subjects: 22
Study 21138606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol-enriched sunflower oil (HSO)
Number of subjects: 22
Study 21138606 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched sunflower oil (Control)
Number of subjects: 22
Study 18483232 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolality iodixanol (n = 61)
Number of subjects: 117
Study 18483232 — intervention group
Group type: COMPARATOR
Intervention: Low-osmolality iopromide (n = 56)
Number of subjects: 117
Study 16943537 — intervention group
Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 133
Study 16943537 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan plus TNF-alpha
Number of subjects: 133
Study 14502085 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg haloperidol (dopaminergic D2 receptor antagonist)
Number of subjects: 7
Study 14502085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11300369 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg for 12 months)
Number of subjects: 1100
Study 11300369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 8982289 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG‐CSF alone
Number of subjects: 18
Study 8982289 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional chemotherapy (C.CHE) + rHuG‐CSF
Number of subjects: 18
Study 8982289 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose cytoxan (HD.CTX) + rHuG‐CSF
Number of subjects: 18
Study 8982289 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 18
Study 1518513 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 11
Study 1518513 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 11
Study 6100597 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-421
Number of subjects: 0
Study 6100597 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 30575407 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine extended-release oral suspension (AMPH EROS) 15, 17.5, or 20 mg
Number of subjects: 18
Study 30575407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29063518 — intervention group
Group type: EXPERIMENTAL
Intervention: ALZ-801 (265 mg twice daily)
Number of subjects: 127